Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

Japanese Encephalitis Virus Vaccination Elicits Cross-Reactive HLA-Class I-Restricted CD8 T Cell Response Against Zika Virus Infection

Japanese Encephalitis Vaccine Generates Cross-Reactive Memory T Cell Responses to Zika Virus in Humans

Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8 + T cells

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine

Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection

Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity

Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

Japanese encephalitis virus inhibits superinfection of Zika virus in cells by the NS2B protein

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Mutation of Putative N-linked Glycosylation Sites in Japanese Encephalitis Virus Premembrane and Envelope Proteins Enhances Humoral Immunity in BALB/C Mice after DNA Vaccination.

An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens

Complement-dependent virion lysis mediated by dengue-Zika virus cross-reactive antibodies correlates with protection from severe dengue disease

Infection of Human Endothelial Cells by Japanese Encephalitis Virus: Increased Expression and Release of Soluble HLA-E

Critical Neutralizing Fragment Of Zika Virus Ediii Elicits Cross-Neutralization And Protection Against Divergent Zika Viruses

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

Delineating Antibody Recognition Against Zika Virus During Natural Infection.

Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohort

Investigation of Immune Response Induction by Japanese Encephalitis Live‐attenuated and Chimeric Vaccines in Mice